<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0601210383
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Penetro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Orodispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        53.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Penetro&trade; contains vardenafil, a member of a class of medicines called<br />phosphodiesterase type 5 inhibitors. They are used for the treatment of<br />erectile dysfunction in adult men, a condition which implies difficulties in<br />getting or keeping an erection.<br />At least one in ten men has trouble getting or keeping an erection at some<br />time. There may be physical or psychological causes, or a mixture of both.<br />Whatever the cause is, due to muscle and blood vessel changes not enough<br />blood stays in the penis to make it hard and keep it hard.<br />Penetro&trade; will only work when you are sexually stimulated. It reduces the<br />action of the natural chemical in your body which makes erections go<br />away. Penetro&trade; allows an erection to last long enough for you to<br />satisfactorily complete sexual activity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- If you are allergic to vardenafil or any of the other ingredients of this<br />medicine (listed in section 6). Signs of an allergic reaction include a rash,<br />itching, swollen face or lips and shortness of breath.<br />- If you are taking medicines containing nitrates, such as glycerol trinitrate<br />for angina, or nitric oxide donors, such as amyl nitrite. Taking these<br />medicines with Penetro&trade; could seriously affect your blood pressure.<br />- If you are taking ritonavir or indinavir, medicines used to treat human<br />immunodeficiency virus (HIV) infections.<br />- If you are over 75 years of age and are taking ketoconazole or<br />itraconazole, anti-fungal medicines.<br />- If you have a severe heart or liver problem.<br />- If you are having kidney dialysis.<br />- If you have recently had a stroke or heart attack.<br />- If you have or have had low blood pressure.<br />- If your family has a history of degenerative eye diseases (such as retinitis<br />pigmentosa).<br />- If you have ever had a condition involving loss of vision due to damage<br />to the optic nerve from insufficient blood supply known as non-arteritic<br />ischemic optic neuropathy (NAION).<br />- If you are taking riociguat. This drug is used to treat pulmonary arterial<br />hypertension (i.e. high blood pressure in the lungs) and chronic<br />thromboembolic pulmonary hypertension (i.e. high blood pressure in the<br />lungs secondary to blood clots). PDE5 inhibitors, such as Penetro&trade; have<br />been shown to increase the hypotensive effects of this medicine. If you are<br />taking riociguat or are unsure tell your doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Penetro&trade;.<br />Take special care with Penetro&trade;<br />- If you have heart trouble. It may be risky for you to have sex.<br />- If you suffer from irregular heart beat (cardiac arrhythmia) or inherited<br />heart diseases affecting your electrocardiogram.<br />- If you have a physical condition affecting the shape of the penis. This<br />includes conditions called angulation, Peyronie&rsquo;s disease and cavernosal<br />fibrosis.<br />- If you have an illness that can cause erections which won&rsquo;t go away<br />(priapism). These include sickle cell disease, multiple myeloma and<br />leukaemia.<br />- If you have stomach ulcers (also called gastric or peptic ulcers).<br />- If you have a bleeding disorder (such as haemophilia).<br />- If you are using any other treatments for erection difficulties.<br />- If you experience sudden decrease or loss of vision, stop taking<br />Penetro&trade; and contact your doctor immediately.<br />Children and adolescents<br />Penetro&trade; is not intended for use by children or adolescents under 18.<br />Other medicines and Penetro&trade;<br />Please tell your doctor or pharmacist if you are using, have recently used<br />or might use any other medicines, including medicines obtained without a<br />prescription.<br />Some medicines may cause problems, especially these:<br />- Nitrates, medicines for angina, or nitric oxide donors, such as amyl<br />nitrite. Taking these medicines with Penetro&trade; could seriously affect your<br />blood pressure.<br />- Medicine for the treatment of arrhythmias, such as quinidine,<br />procainamide, amiodarone or sotalol.<br />- Ritonavir or indinavir, medicines for HIV.<br />- Ketoconazole or itraconazole, anti-fungal medicines<br />- Erythromycin or clarithromycin, macrolide antibiotics<br />- Alpha-blockers, a type of medicine used to treat high blood pressure and<br />enlargement of the prostate (as benign prostatic hyperplasia).<br />- Riociguat.<br />Do not use Penetro&trade; Orodispersible tablets combined with any other<br />treatment for erectile dysfunction.<br />Penetro&trade; with food, drink and alcohol<br />- You can take Penetro&trade; with or without food but preferably not after a<br />heavy or high-fat meal as this may delay the effect.<br />- Don&rsquo;t drink grapefruit juice when you use Penetro&trade;. It can interfere<br />with the usual effect of the medicine.<br />- Alcoholic drink can make erection difficulties worse.<br />Pregnancy and breast-feeding<br />Penetro&trade; is not for use by women.<br />Driving and using machines<br />Penetro&trade; might make some people feel dizzy or affect their vision. If you<br />feel dizzy, or if your vision is affected after taking Penetro&trade; don&rsquo;t drive<br />or operate any tools or machines.<br />Penetro&trade; 10 mg orodispersible tablets contains Aspartame and<br />Sorbitol.<br />- Aspartame: This medicine contains aspartame. Aspartame is a source of<br />phenylalanine. It may be harmful if you have phenylketonuria (PKU), a<br />rare genetic disorder in which phenylalanine builds up because the body<br />cannot remove it properly.<br />- Sorbitol: This medicine contains sorbitol.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure. The recommended dose is<br />10 mg.<br />Take a Penetro&trade; tablet about 25 to 60 minutes before sexual activity.<br />With sexual stimulation you may achieve an erection anywhere from<br />25 minutes up to four to five hours after taking Penetro&trade;.<br />- Do not remove the orodispersible tablet from the blister until you are<br />going to take it. With dry hands press gently to release the tablet on your<br />hand. Do not crush the tablet.<br />- Place the entire orodispersible tablet in the mouth, on the tongue, where<br />it will dissolve in seconds, then swallow with saliva. The orodispersible<br />tablet must be taken without any liquid.<br />Do not take Penetro&trade; Orodispersible tablets with any other forms of<br />vardenafil.<br />Do not take Penetro&trade; more than once a day.<br />Tell your doctor if you think Penetro&trade; is too strong or too weak.<br />If you take more Penetro&trade; than you should<br />Men who take too much Penetro&trade; may experience more side effects or<br />may get severe back pain. If you take more Penetro&trade; than you should, tell<br />your doctor.</p><p>If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them. Most of the effects are mild or moderate.<br />Partial, sudden, temporary or permanent decrease or loss of vision in one<br />or both eyes has been experienced by patients. Stop taking Penetro&trade; and<br />contact your doctor immediately. Sudden decrease or loss of hearing has<br />been reported.<br />Cases of sudden death, fast or altered heart beat, heart attack, chest pain,<br />and trouble in cerebral circulation (including temporarily decreased blood<br />flow to parts of the brain and bleeding in the brain) have been reported in<br />men taking vardenafil. Most of the men who experienced these side<br />effects had heart problems before taking this medicine. It is not possible<br />to determine whether these events were directly related to vardenafil.<br />The chance of having a side effect is described by the following<br />categories:<br />Very common:<br />may affect more than 1 in 10 users<br />- Headache<br />Common:<br />may affect up to 1 in 10 users<br />- Dizziness - Flushing - Blocked or runny nose - Indigestion<br />Uncommon:<br />may affect up to 1 in 100 users<br />- Swelling of skin and mucous tissue including swollen face, lips or throat<br />- Sleep disorder<br />- Numbness and impaired perception of touch<br />- Sleepiness<br />- Effects on vision, redness of the eye, effects on colour vision, eye pain<br />and discomfort, light sensitivity<br />- Ringing in the ears, vertigo<br />- Fast heart beat or pounding heart<br />- Breathlessness<br />- Stuffy nose<br />- Acid reflux, gastritis, abdominal pain, diarrhoea, vomiting; feeling sick<br />(nausea), dry mouth<br />- Raised levels of liver enzymes in your blood<br />- Rash, reddened skin<br />- Back or muscle pain, increase in blood of a muscle enzyme (creatine<br />phosphokinase), muscle stiffness<br />- Prolonged erections<br />- Malaise<br />Rare:<br />may affect up to 1 in 1,000 users<br />- Inflammation of the eyes (conjunctivitis)<br />- Allergic reaction<br />- Anxiety<br />- Fainting<br />- Amnesia<br />- Seizure<br />- Increased pressure in the eye (glaucoma), lacrimation increased<br />- Effects on the heart (such as heart attack, altered heart beat or angina)<br />- High or low blood pressure<br />- Nose bleed<br />- Effect on results of blood tests to check liver function<br />- Sensitivity of the skin to sun light<br />- Painful erections<br />- Chest pain<br />Very rare or not known:<br />may affect less than 1 in 10,000 users or frequency cannot be estimated<br />from the available data<br />- Blood in the urine (Haematuria)<br />- Penile bleeding (Penile Haemorrhage)<br />- Presence of blood in the semen (Haematospermia)<br />- Sudden death<br />- Bleeding in the brain<br />Reporting of side effects<br />If you get any side effects, talk to your doctor. This includes any possible<br />side effects not listed in this leaflet. By reporting side effects, you can<br />help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the<br />carton after &ldquo;EXP&rdquo;.<br />&bull; Do not store above 30 &deg;C.<br />&bull; Store in the original package in order to protect from humidity and light.<br />&bull; Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is vardenafil.<br />Each orodispersible tablet contains Vardenafil 10 mg<br />(as hydrochloride).<br />- The other ingredients of the tablets are:<br />Mannitol, Sorbitol, Maltitol, Crospovidone, Copovidone Silicon Dioxide,<br />Aspartame, Peppermint Flavor and Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Penetro™ Orodispersible tablets are White to off white, round tablets,
debossed with "JP" on one side and "213" on other side.
Penetro™ 10mg Orodispersible tablets available in a box of 4 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11-11-2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي عقار بینترو&nbsp;على فاردینافیل والذي ینتمي إلى مجموعة الأدویة التي تُسمى مثبّطات&nbsp;</p><p>الفسفودایستراز من النوع الخامس. حیث یستخدم ھذا العقار لعلاج الاختلال الوظیفي الانتصابي<br />في الرجال البالغین، وھي حالة تتضمن مشكلات في تحقیق الانتصاب الكامل والحفاظ علیھ.<br />یعاني شخص واحد على الأقل من بین كل عشرة أشخاص من الرجال من صعوبة في تحقیق<br />الانتصاب أو الحفاظ علیھ في بعض الأحیان. قد یرجع ذلك لأسباب جسدیة أو نفسیة، أو مزیج من<br />ا كان السبب، فنتیجة لحدوث تغیرات في العضلات والأوعیة الدمویة، لا یصل الدم 􀌒 الاثنین. أی<br />الكافي إلى القضیب (العضو الذكري) لجعلھ منتصبًا والحفاظ على الانتصاب.</p><p>سوف یعمل عقار بینترو&nbsp;عندما تحدث لك إثارة جنسیًة. حیث أنھ یقلل فعالیة المادة الكیمیائیة&nbsp;</p><p>الطبیعیة في جسمك التي تجعل الانتصاب یضعف و ینقضي. یسمح عقار بینترو&nbsp;للانتصاب أن&nbsp;یدوم لمدة كافیة للقیام بنشاط جنسي كامل علي نحو جید.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- إذا كنت تعاني من حساسیة تجاه مادة فاردینافیل أو تجاه أيّ مكوّن من المكوّنات الأخرى الداخلة<br />في تركیب ھذا الدَّواء (المُدرجة في القسم رقم ٦). تشتمل علامات تفاعلات الحساسیة على طفح<br />جلدي أو حكة أو تورم في الوجھ أو الشفتین أو ضیق بالتنفس.<br />- إذا كنت تتناول أي تركیبة دوائیة تحتوي على النترات مثل ثلاثي نترات الجلیسیرول لعلاج<br />الذبحة الصدریة، أو الأدویة التي تحتوي على أكسید النیتریك مثل نتریت الأمیل. حیث یمكن أن<br />بشكل خطیر على ضغط الدم. &trade; یؤثر تناول ھذه الأدویة مع عقار بینترو<br />- إذا كنت تتناول ریتونافیر أو إندینافیر، الأدویة التي تُستخدم لعلاج حالات عدوى فیروس نقص<br />.(HIV) المناعة البشریة<br />- إذا كان عمرك یتجاوز ۷٥ عامًا وكنت تتناول عقار كیتوكونازول أو إیتراكونازول ، أدویة<br />مضادة للفطریات.<br />- إذا كنت تعاني من مشكلة شدیدة في القلب أو الكبد.<br />- إذا كنت تخضع لغسیل الكلى.<br />- إذا كنت قد تعرضت مؤخرًا لسكتة دماغیة أو نوبة قلبیة.<br />- إذا كنت تعاني أو سبق أن عانیت من انخفاض في ضغط الدم.<br />- إذا كانت عائلتك لدیھا تاریخ مرضي من أحد أشكال أمراض العیون التنكسیة (مثل التھاب<br />الشبكیة الصباغي- عشى لیلي).<br />- إذا سبق لك أن عانیت من أيّ حالة تتضمن فقدان البصر بسبب تلف العصب البصري الناتج عن<br />.(NAION) عدم كفایة إمداد الدم؛ المعروف باعتلال عصبي بصري إقفاري غیر شریاني<br />- إذا كنت تتناول دواء ریوسیجوات الذي یُستخدم في علاج ارتفاع ضغط الدم الشریاني الرئوي<br />(أي ارتفاع ضغط الدم في الرئتین) وارتفاع ضغط الدم الرئوي الناجم عن الانصمام الرئوي<br />المزمن (أي ارتفاع ضغط الدم في الرئتین الناجم عن تكون جلطات دمویة). حیث أثبتت الدراسات<br />تزید من الآثار &trade; مثل عقار بینترو (PDE أن مثبطات إنزیم فسفودایستراز من النوع الخامس ( 5<br />الخافضة لضغط الدم لھذا الدواء. إذا كنت تتناول أدویة ریوسیجوات أو لم تكن متأكدًا مما إذا كنت<br />تتناولھا أم لا فاستشر طبیبك.<br />تحذیرات واحتیاطات<br />.&trade; استشر طبیبك أو الصیدلي قبل تناول عقار بینترو<br />في الحالات التالیة: &trade; توخ حذرًا خاصًا عند تناول عقار بینترو<br />- إذا كنت تعاني من اضطراب بالقلب. فقد یعرضك ممارسة الجنس للخطورة.<br />- إذا كنت تعاني من عدم انتظام ضربات القلب (اضطراب النظم القلبیة) أو أى أمراض قلب<br />وراثیة تؤثرعلى الرسم الكھربائي للقلب.<br />- إذا كان لدیك حالة جسدیة تؤثر على شكل القضیب (العضو الذكري). مثل التَّزوي (میل العضو<br />الذكري)، مرض البِیروني، وتلیّف النسیج الكھفي للقضیب.<br />- إذا كنت تعاني من مرض یمكن أن یسبب الانتصاب المستمر (القساح). وتتضمن ھذه الآثار<br />الجانبیة فقر الدم المنجلي، الورم النقوي المتعدد، وسرطان الدم.<br />- إذا كنت تعاني من قرحة في المعدة (وتسمى أیضًا قًرْحات مَعِدِیة أو ھضمیة).<br />- إذا كنت تعاني من اضطراب نزفي (مثل الھیموفیلیا).<br />- إذا كنت تستخدم أیّة أدویة أخرى لعلاج مشاكل الانتصاب.<br />واتصل بطبیبك &trade; - إذا عانیت من ضعف أو فقدان مفاجئ للرؤیة، فتوقف عن تناوُل عقار بینترو<br />على الفور.<br />المرضى من الأطفال والمراھقین<br />غیر مخصّص للاستخدام في الأطفال أو المراھقین الذین تقل أعمارھم عن ۱۸ سنة. &trade; عقار بینترو<br />&trade; تناول أدویة أخرى مع عقار بینترو<br />یُرجى إبلاغ طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى،<br />بما في ذلك الأدویة التي تم الحصول علیھا بدون وصفة طبیة.<br />قد تتسبب بعض الأدویة في حدوث مشكلات، وعلى وجھ الخصوص الأدویة التالیة:<br />- أي تركیبة من تركیبات النیترات، أدویة علاج الذبحة الصدریة أو الأدویة التي تحتوي<br />على موفرات أكسید النیتریك مثل نتریت الأمیل. حیث یمكن أن یؤثر تناول ھذه الأدویة<br />بشكل خطیر على ضغط الدم لدیك. &trade; مع عقاربینترو<br />- كینیدین، بروكایینامید، أمیودارون أو سوتالول، أدویة لعلاج اضطراب نبضات القلب.<br />.(HIV) - ریتونافیر أو إندینافیر، أدویة لعلاج فیروس نقص المناعة البشریة<br />- كیتوكونازول، إیتراكونازول، أدویة مضادّة للفطریات.<br />- إریثرومیسین أو كلاریثرومیسین، مضادّات حیویة ماكرولیدیة.<br />- حاصرات ألفا، وھو نوع من الأدویة التي تستخدم لعلاج ارتفاع ضغط الدم وتضخّم البروستاتا<br />(مثل تضخم البروستاتا الحمید).<br />- عقار ریوسیجوات.<br />القابلة للذوبان بالفم مع أیّة أدویة أخرى لعلاج ضعف &trade; یجب عدم استخدام أقراص بینترو<br />الانتصاب.<br />مع الأغذیة والمشروبات والكحولیات &trade; تناوُل عقار بینترو<br />مع الطعام أو بدونھ ولكن یفضل عدم تناولھ بعد وجبة ثقیلة أو عالیة &trade; - یمكنك تناول عقار بینترو<br />الدھون لأن ذلك قد یؤخر تأثیر العقار.<br />حیث یمكن أن یتعارض ذلك مع .&trade; - تجنب شرب عصیر الجریب فروت عند تناول عقار بینترو<br />التأثیر المعتاد للدواء.<br />- یمكن أن یؤدي شرب الكحولیات إلى تفاقم مشكلة الانتصاب وجعلھا تزداد سوءًا.<br />الحمل والرضاعة الطبیعیة<br />لا یستخدم من قبل السیدات. &trade; عقار بینترو<br />القیادة واستخدام الآلات<br />على الرؤیة لدى بعض الأشخاص أو یجعلھم یشعرون بالدوخة. لذا، &trade; قد یؤثر تناوُل عقار بینترو<br />تجنب القیادة أو استخدام أیّة أدوات أو آلات إذا كنت تشعر بدوخة أو اضطرابات في الرؤیة بعد<br />.&trade; تناول عقار بینترو<br />۱۰ ملجم أقراص قابلة للذوبان بالفم (أقراص تذوب في الفم بدون مضغ &trade; یحتوي عقار بینترو<br />وبدون حاجة إلى شرب الماء) على أسبرتام و سوربیتول.<br />- أسبارتام: یحتوي ھذا العقار على الأسبارتام. یعد الأسبارتام أحد مصادر الفینیل ألانین، وقد<br />وھو اضطراب وراثي نادر ،(PKU) یكون استخدامھ ضارًا إذا كنت تعاني من بِیلَةُ الفینیل كیتون<br />یتراكم خلالھ الفینیل ألانین لأن الجسم لا یستطیع التخلص منھ بشكل صحیح.<br />- سوربیتول: یحتوي ھذا العقار السوربیتول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك طبیبك. استشر طبیبك أو الصیدلي إذا لم تكن متأكدًا من<br />كیفیة التناول. الجرعة المُوصى بھا ھي ۱۰ ملجم.<br />قبل القیام بأي نشاط جنسي بفترة زمنیة تتراوح من ۲٥ إلى ٦۰ دقیقة &trade; تناول قرص من بینترو<br />تقریبًا. قد یتم تحقیق الانتصاب مع التحفیز الجنسي في أي وقت خلال فترة زمنیة تتراوح من ۲٥<br />.&trade; دقیقة إلى ٤ أو ٥ ساعات بعد تناول بینترو<br />لا تقم بإخراج القرص المتفتت فمویَّا من الشریط قبل أن تكون مستعدًا لتناولھ. اضغط برفق بیدیك<br />وھي غیر مبللة بالماء لإخراج القرص على یدك. لا تقم بسحق القرص أو تكسیره.<br />ضع القرص القابل للتفتت كاملاَ داخل الفم، على اللسان، حیث سیتفتّت بسرعة خلال ثوان، ثم<br />ابتلعھ مع اللعاب. یجب أن یتم تناول القرص بدون شرب أي سائل.<br />القابلة للذوبان بالفم مع أي شكل أخر من أشكال فاردینافیل. &trade; لا تتناول أقراص بینترو<br />أكثر من مرة واحدة في الیوم. &trade; لا تتناول عقار بینترو<br />قوي أو ضعیف جدًا. &trade; أخبر طبیبك إذا كنت ترى أن تأثیر عقار بینترو<br />&trade; إذا تناولت كمیة أكثر مما یجب من عقار بینترو<br />من آثار جانبیة &trade; قد یعاني المرضى من الرجال ممن یتناولون كمیة أكثر مما یجب من عقار بینترو<br />أكثر أو قد یصابون بألم شدید في الظھر. أخبر طبیبك أو الصیدلي إذا تناولت كمیة أكثر مما یجب<br />.&trade; من عقار بینترو<br />إذا كانت لدیك أیّة أسئلة إضافیة حول استخدام ھذا الدواء، فاستشر طبیبك أو الصیدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء، مثلھ مثل كافة الأدویة، آثارًا جانبیة على الرغم من عدم حدوثھا لدى الجمیع.<br />تكون معظم ھذه الآثار معتدلة أو متوسطة.<br />لقد عانى المرضى من انخفاض جزئي أو مفاجئ أو مؤقت أو دائم أو فقدان للرؤیة في إحدى<br />والاتصال بطبیبك على &trade; العینین أو كلتیھما. یجب علیك حینئذٍ التوقف عن تناول عقار بینترو<br />الفور. لقد تم الإبلاغ أیضًا عن انخفاض أو فقدان مفاجئ لحاسة السمع.</p><p>تم الإبلاغ عن حالات الوفاة المفاجئة ، أو النبض القلبي السریع أو المتغیر ، والنوبات القلبیة ، ألم<br />في الصدر ، ومشاكل في الدورة الدمویة الدماغیة (بما في ذلك انخفاض تدفق الدم مؤقتًا إلى<br />أجزاء من المخ ونزیف في المخ) عند الرجال الذین یتناولون فاردینافیل. كان معظم الرجال الذین<br />عانوا من ھذه الآثار الجانبیة یعانون من مشاكل في القلب قبل تناول ھذا الدواء. لا یمكن تحدید ما<br />إذا كانت ھذه الأحداث مرتبطة مباشرة بفاردینافیل.<br />یتم توضیح الآثار الجانبیة المُحتملة من خلال الفئات التالیة:<br />دا: 􀌒 شائعة ج<br />قد تُؤثر على أكثر من شخص واحد من بین كل ۱۰ مستخدمین:<br />- صداع.<br />شائعة:<br />قد تُؤثر على ما یصل إلى شخص واحد من بین كل ۱۰ مستخدمین:<br />- دوار.<br />- توھج (تدفق الدم في الوجھ).<br />- انسداد أو سیلان الأنف.<br />- عسر الھضم.<br />غیر شائعة:<br />قد تُؤثر على ما یصل إلى شخص واحد من بین كل ۱۰۰ مستخدم<br />- تورم الجلد والأنسجة المخاطیة تشمل تورم الوجھ، الشفتین أو الحلق.<br />- اضطراب النوم.<br />- اخدرار و اختلال إدراك اللمس.<br />- نعاس.<br />- تأثیر على الرؤیة، احمرار العین، التأثیر على رؤیة الألوان، ألم وشعور بعدم ارتیاح في العین،<br />حساسیة تجاه الضوء.<br />- طنین في الأذنین، دُوار<br />- سرعة ضربات القلب أو تسارع دقّات القلب.<br />- صعوبة التَّنَفُّس.<br />- انسداد الأنف.<br />- ارتجاع أحماض المعدة، التھاب المعدة، آلام في البطن، إسھال، قيء، شعور بإعیاء (غثیان)،<br />جفاف الفم.<br />- ارتفاع مستوى إنزیمات الكبد في الدم<br />- طفح جلدي، احمرار الجلد<br />- آلام الظھر أو العضلات، زیادة تركیز أحد إنزیمات العضلات (انزیم فسفوكیناز الكریاتین)<br />بالدم، تیبس العضلات.<br />- انتصاب لفترة طویلة.<br />- شعور بتَوَعُّك</p><p>نادرة:<br />قد تُؤثر على ما یصل إلى شخص واحد من بین كل ۱٫۰۰۰ مستخدم<br />- التھاب العینین (التھاب الملتحمة)<br />- تفاعلات تحسسیة<br />- شعور بقلق<br />- إغماء<br />- فقدان الذاكرة<br />- نوبة صرع<br />- زیادة ضغط العین (الزرق)، زیادة إدماع العین<br />- تأثیر على القلب (مثل نوبة قلبیة، تغیر نبض القلب أو ذبحة صدریة)<br />- ارتفاع أو انخفاض ضغط الدم<br />- نزیف من الأنف<br />- تأثیر على نتائج اختبارات الدم لفحص وظائف الكبد<br />- حساسیة الجلد لضوء الشمس<br />- انتصاب مؤلم<br />- ألم في الصدر<br />دا أوغیر معروف معدّل تكرارھا: 􀌒 نادرة ج<br />قد تُؤثر على أقل من شخص واحد من بین كل ۱۰٫۰۰۰ مستخدم أو لا یمكن تقدیر معدّل<br />تكرارھا من واقع البیانات المتاحة<br />- وجود دم بالبول (تبوّل دموي)<br />- نزیف القضیب (نزیف قضیبي)<br />- وجود دم في السائل المنوي (تدمّم المَنِيّ).<br />- موت مفاجئ<br />- نزیف في المخ<br />الإبلاغ عن الآثار الجانبیة<br />إذا أُصبت بأیّة آثار جانبیة، فتحدَّث إلى طبیبك. یشمل ذلك أیّة آثار جانبیة مُحتمَلة غیر مُدرجة في<br />ھذه النَّشرة. من خلال إبلاغك عن الآثار الجانبیة، یمكنك المُساعدة في توفیر معلومات إضافیة<br />حول أمان استخدام ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; یحفظ بعیدًا عن متناول و مرأى الأطفال.<br />&bull; لا تستخدم ھذا الدَّواء بعد انتھاء تاریخ الصلاحیة المدوّن على العبوة الكرتونیة بعد كلمة<br />.&quot;EXP&quot;<br />م. &ordm; &bull; یحفظ في درجة حرارة لا تزید عن ۳۰<br />&bull; یحفظ في العبوة الأصلیة للحمایة من الرطوبة و الضوء.<br />&bull; لا تقمْ بالتخلص من الأدویة عن طریق إلقائھا في میاه الصرف أو مع المخلفات المنزلیة.<br />استشر الصیدلي الخاص بك حول كیفیة التَّخلص من الأدویة التي لم تعد بحاجة إلیھا. حیث تُساعد<br />ھذه التدابیر في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا یحتوي عقار بینترو<br />- المادة الفعالة ھي فاردینافیل<br />یحتوي كل قرص قابل للذوبان بالفم على ۱۰ ملجم فاردینافیل (على ھیئة ھیدروكلورید ).<br />- المكونات الأخرى للأقراص ھي: مانیتول، سوربیتول، مالتیتول، كروسبوفیدون، سیلكا غرویة<br />مائیة، أسبارتام، نكھة النعناع، ستیرات الماغنیسیوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">یتوفر عقار بینترو ۱۰ ملجم في شكل أقراص قابلھ للذوبان بالفم لونھا أبیض إلى أبیض باھت،&nbsp;مستدیرة الشكل, محفور على أحد جانبیھا `JP`&nbsp;و على الجانب الآخر `213`</p><p style="text-align:right">تتوفر الأقراص في عبوة تحتوي على ٤ أقراص.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>&nbsp;هاتف: 6081111-12-966+</p><p>&nbsp;فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني www.jamjoompharma.como<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11-11-2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Penetro 10 mg Orodispersible Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each orodispersible tablet contains 10 mg of vardenafil (as hydrochloride).
Excipients: 1.80 mg aspartame per orodispersible tablet.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orodispersible Tablets
White to off white, round tablets debossed with "JP” on one side and "213" on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve or<br />maintain a penile erection sufficient for satisfactory sexual performance.<br />In order for Penetro to be effective, sexual stimulation is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The maximum dose for Penetro Orodispersible tablet is 10 mg/day.<br />Use in adult men<br />Penetro 10 mg Orodispersible tablets are taken as needed approximately 25 to 60 minutes before<br />sexual activity.<br />Special populations<br />Elderly (&ge;65 years old)<br />Dose adjustments are not required in elderly patients. However, an increase to a maximum dose of<br />Penetro 10 mg Orodispersible Tablets be carefully considered depending on the individual tolerability<br />(see sections 4.4 and 4.8).</p><p>Hepatic impairment<br />Penetro 10 mg Orodispersible tablets are not indicated as a starting dose in patients with mild hepatic<br />impairment (Child-Pugh A).<br />Patients with mild hepatic impairment should start treatment with Vardenafil 5 mg film-coated tablets.<br />Based on tolerability and efficacy, the dose may be increased to Vardenafil 10 mg and 20 mg filmcoated<br />tablets, or Vardenafil 10 mg orodispersible tablets.<br />The maximum dose recommended in patients with moderate hepatic impairment (Child-Pugh B) is<br />Vardenafil 10 mg as film-coated tablets (see section 5.2).<br />Penetro 10mg Orodispersible tablets are not for use in patients with moderate (Child-Pugh B) and<br />severe hepatic impairment (Child-Pugh C; see section 4.3).<br />Renal impairment<br />No dose adjustment is required in patients with mild to moderate renal impairment.<br />In patients with severe renal impairment (creatinine clearance &lt;30 ml/min) a starting dose of<br />Vardenafil 5 mg film-coated tablets should be considered. Based on tolerability and efficacy, the dose<br />may be increased to Vardenafil 10 mg and 20 mg film-coated tablets, or Penetro 10 mg Orodispersible<br />tablets.<br />Penetro Orodispersible tablet is not for use in patients with end-stage renal failure (see section 4.3).<br />Paediatric population<br />Penetro Orodispersible tablets are not indicated for individuals below 18 years of age. There is no<br />relevant indication for use of Penetro Orodispersible tablets in children and adolescents.<br />Use in patients using other medicinal products<br />Concomitant use of moderate or potent CYP 3A4 inhibitors<br />Vardenafil dose adjustment is necessary if moderate or potent CYP 3A4 inhibitors are given<br />concomitantly (see section 4.5).<br />Method of administration<br />For oral use.</p><p>The orodispersible tablet should be placed in the mouth on the tongue, where it will rapidly<br />disintegrate, and then swallowed. Penetro Orodispersible tablets must be taken without liquid and<br />immediately upon release from the blister.<br />Penetro Orodispersible tablets can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
The co-administration of vardenafil with nitrates or nitric oxide donors (such as amyl nitrite) in any
form is contraindicated (see sections 4.5 and 5.1).
Penetro is contraindicated in patients who have loss of vision in one eye because of non-arteritic
anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or
not with previous phosphodiesterase 5 (PDE5) inhibitor exposure (see section 4.4).
Medicinal products for the treatment of erectile dysfunction should generally not be used in men for
whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable
angina or severe cardiac failure [New York Heart Association III or IV]).
The safety of vardenafil has not been studied in the following sub-groups of patients and its use is
therefore contraindicated until further information is available:
- severe hepatic impairment (Child-Pugh C),
- end stage renal disease requiring dialysis,
- hypotension (blood pressure <90/50 mmHg),
- recent history of stroke or myocardial infarction (within the last 6 months),
- unstable angina, and
- known hereditary retinal degenerative disorders such as retinitis pigmentosa.
Concomitant use of vardenafil with the potent CYP3A4 inhibitors ketoconazole and itraconazole (oral
form) is contraindicated in men older than 75 years.
Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is
contraindicated, as they are very potent inhibitors of CYP3A4 (see section 4.5).
The co-administration of PDE5 inhibitors, including vardenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction and<br />determine potential underlying causes, before pharmacological treatment is considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular<br />status of their patients, since there is a degree of cardiac risk associated with sexual activity (see<br />section 4.3). Vardenafil has vasodilator properties, resulting in mild and transient decreases in blood<br />pressure (see section 5.1). Patients with left ventricular outflow obstruction, e.g. aortic stenosis and<br />idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators including Type<br />5 phosphodiesterase inhibitors.<br />Serious cardiovascular events including sudden death, tachycardia, myocardial infarction, ventricular<br />tachy-arrythmia, angina pectoris, and cerebrovascular disorders [including transient ischaemic attack<br />and cerebral haemorrhage], have been reported in temporal association with vardenafil. Most of the<br />patients in whom these events have been reported had pre-existing cardiovascular risk factors.<br />However, it is not possible to definitively determine whether these events are related directly to these<br />risk factors, to vardenafil, to sexual activity, or to a combination of these or other factors.<br />Medicinal products for the treatment of erectile dysfunction should be used with caution in patients<br />with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie&#39;s<br />disease), or in patients who have conditions which may predispose them to priapism (such as sickle<br />cell anaemia, multiple myeloma or leukaemia).<br />The safety and efficacy of combinations of Vardenafil orodispersible tablets with Vardenafil filmcoated<br />tablets or other treatments for erectile dysfunction have not been studied. Therefore the use of<br />such combinations is not recommended.<br />Tolerability of the maximum dose of Vardenafil 20 mg film-coated tablets may be lower in elderly<br />patients (&ge; 65 years old) (see sections 4.2 and 4.8).<br />Concomitant use of alpha-blockers<br />The concomitant use of alpha-blockers and vardenafil may lead to symptomatic hypotension in some<br />patients because both are vasodilators. Concomitant treatment with vardenafil should only be initiated&nbsp;if the patient has been stabilised on his alpha-blocker therapy. In those patients who are stable on<br />alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg<br />film-coated tablets. Patients treated with alpha-blockers should not use Vardenafil 10 mg<br />orodispersible tablets as a starting dose. Vardenafil may be administered at any time with tamsulosin<br />or with alfuzosin. With other alpha-blockers a time separation of dose should be considered when<br />vardenafil is prescribed concomitantly (see section 4.5). In those patients already taking an optimised<br />dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in<br />alpha-blocker dose may be associated with further lowering of blood pressure in patients taking<br />vardenafil.<br />Concomitant use of CYP3A4 inhibitors<br />Concomitant use of vardenafil with potent CYP 3A4 inhibitors such as itraconazole and ketoconazole<br />(oral form) should be avoided as very high plasma concentrations of vardenafil are reached if the<br />medicinal products are combined (see sections 4.5 and 4.3).<br />Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as erythromycin<br />and clarithromycin, are given concomitantly (see section 4.2 and 4.5).<br />Concomitant intake of grapefruit or grapefruit juice is expected to increase the plasma concentrations<br />of vardenafil. The combination should be avoided (see section 4.5).<br />Effect on QTc interval<br />Single oral doses of 10 mg and 80 mg of vardenafil have been shown to prolong the QTc interval by a<br />mean of 8 msec and 10 msec, respectively. And single doses of 10 mg vardenafil co-administered<br />concomitantly with 400 mg gatifloxacin, an active substance with comparable QT effect, showed an<br />additive QTc effect of 4 msec when compared to either active substance alone. The clinical impact of<br />these QT changes is unknown (see section 5.1).</p><p>The clinical relevance of this finding is unknown and cannot be generalised to all patients under all<br />circumstances, as it will depend on the individual risk factors and susceptibilities that may be present<br />at any time in any given patient. Medicinal products that may prolong QTc interval, including<br />vardenafil, are best avoided in patients with relevant risk factors, for example, hypokalaemia,<br />congenital QT prolongation, concomitant administration of antiarrhythmic medicinal products in Class<br />IA (e.g. quinidine, procainamide), or Class III (e.g. amiodarone, sotalol).<br />Effect on vision&nbsp;Visual defects and cases of non-arteritic ischemic optic neuropathy (NAION) have been reported in<br />connection with the intake of Vardenafil and other PDE5 inhibitors. Analyses of observational data<br />suggest an increased risk of acute NAION in men with erectile dysfunction following exposure to<br />PDE5 inhibitors such as vardenafil, tadalafil and sildenafil (see section 4.8). As this may be relevant<br />for all patients exposed to vardenafil the patient should be advised that in the case of sudden visual<br />defect, he should stop taking Penetro Orodispersible tablets and consult immediately a physician (see<br />section 4.3).<br />Effect on bleeding<br />In vitro studies with human platelets indicate that vardenafil has no antiaggregatory effect on its own,<br />but at high (super-therapeutic) concentrations vardenafil potentiates the antiaggregatory effect of the<br />nitric oxide donor sodium nitroprusside. In humans, vardenafil had no effect on bleeding time alone or<br />in combination with acetylsalicylic acid (see section 4.5). There is no safety information available on<br />the administration of vardenafil to patients with bleeding disorders or active peptic ulceration.<br />Therefore vardenafil should be administered to these patients only after careful benefit-risk<br />assessment.<br />Aspartame<br />This medicine contains 1.80 mg aspartame in each 10 mg orodispersible tablet. Aspartame is a source<br />of phenylalanine. It may be harmful for people with phenylketonuria (PKU), a rare genetic disorder in<br />which phenylalanine builds up because the body cannot remove it properly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other medicinal products on vardenafil<br />In vitro studies<br />Vardenafil is metabolised predominantly by hepatic enzymes via cytochrome P450 (CYP) isoform<br />3A4, with some contribution from CYP3A5 and CYP2C isoforms. Therefore, inhibitors of these<br />isoenzymes reduce vardenafil clearance.<br />In vivo studies<br />Co-administration of the HIV protease inhibitor indinavir (800 mg three times a day), a potent<br />CYP3A4 inhibitor, with vardenafil (10 mg film-coated tablets) resulted in a 16-fold increase in<br />vardenafil AUC and a 7-fold increase in vardenafil Cmax. At 24 hours, the plasma levels of vardenafil<br />had fallen to approximately 4% of the maximum vardenafil plasma level (Cmax).</p><p>Co-administration of vardenafil with ritonavir (600 mg twice daily) resulted in a 13-fold increase in<br />vardenafil Cmax and a 49-fold increase in vardenafil AUC0-24 when co-administered with vardenafil<br />5 mg. The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir,<br />a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9. Ritonavir significantly prolonged the<br />half-life of vardenafil to 25.7 hours (see section 4.3).<br />Co-administration of ketoconazole (200 mg), a potent CYP3A4 inhibitor, with vardenafil (5 mg)<br />resulted in a 10-fold increase in vardenafil AUC and a 4-fold increase in vardenafil Cmax (see section<br />4.4).<br />Although specific interaction studies have not been conducted, the concomitant use of other potent<br />CYP3A4 inhibitors (such as itraconazole) can be expected to produce vardenafil plasma levels<br />comparable to those produced by ketoconazole. Concomitant use of vardenafil with potent CYP3A4<br />inhibitors such as itraconazole and ketoconazole (oral use) should be avoided (see sections 4.3 and<br />4.4). In men older than 75 years the concomitant use of vardenafil with itraconazole or ketoconazole is<br />contraindicated (see section 4.3).<br />Co-administration of erythromycin (500 mg three times a day), a CYP3A4 inhibitor, with vardenafil (5<br />mg) resulted in a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax. Although a<br />specific interaction study has not been conducted, the co-administration of clarithromycin can be<br />expected to result in similar effects on vardenafil AUC and Cmax. When used in combination with a<br />moderate CYP3A4 inhibitor such as erythromycin or clarithromycin, vardenafil dose adjustment might<br />be necessary (see sections 4.2 and 4.4).<br />Cimetidine (400 mg twice daily), a non-specific cytochrome P450 inhibitor, had no effect on<br />vardenafil AUC and Cmax when co-administered with vardenafil (20 mg) to healthy volunteers.<br />Grapefruit juice being a weak inhibitor of CYP3A4 gut wall metabolism, may give rise to modest<br />increases in plasma levels of vardenafil (see section 4.4).</p><p>The pharmacokinetics of vardenafil (20 mg) was not affected by co-administration with the H2-<br />antagonist ranitidine (150 mg twice daily), digoxin, warfarin, glibenclamide, alcohol (mean maximum<br />blood alcohol level of 73 mg/dl) or single doses of antacid (magnesium hydroxide/aluminium<br />hydroxide).<br />Although specific interaction studies were not conducted for all medicinal products, population<br />pharmacokinetic analysis showed no effect on vardenafil pharmacokinetics of the following<br />concomitant medicinal products: acetylsalicylic acid, ACE-inhibitors, beta-blockers, weak CYP3A4&nbsp;inhibitors, diuretics and medicinal products for the treatment of diabetes (sulfonylureas and<br />metformin).<br />Effects of vardenafil on other medicinal products<br />There are no data on the interaction of vardenafil and non-specific phosphodiesterase inhibitors such<br />as theophylline or dipyridamole.<br />In vivo studies<br />No potentiation of the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) was<br />observed when vardenafil (10 mg) was given at varying time intervals (1 h to 24 h) prior to the dose of<br />nitroglycerin in a study in 18 healthy male subjects. Vardenafil 20 mg film-coated tablets potentiated<br />the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 1 and 4 hours after<br />vardenafil administration to healthy middle aged subjects. No effect on blood pressure was observed<br />when nitroglycerin was taken 24 hours after administration of a single dose of vardenafil 20 mg filmcoated<br />tablets. However, there is no information on the possible potentiation of the hypotensive effects<br />of nitrates by vardenafil in patients, and concomitant use of Penetro Orodispersible tablets and nitrates<br />is therefore contraindicated (see section 4.3).<br />Nicorandil is a hybrid of potassium channel opener and nitrate. Due to the nitrate component it has the<br />potential to have serious interaction with vardenafil.<br />Since alpha-blocker monotherapy can cause marked lowering of blood pressure, especially postural<br />hypotension and syncope, interaction studies were conducted with vardenafil. In two interaction<br />studies with healthy normotensive volunteers after forced titration of the alpha-blockers tamsulosin or<br />terazosin to high doses, hypotension (in some cases symptomatic) was reported in a significant number<br />of subjects after co-administration of vardenafil. Among subjects treated with terazosin, hypotension<br />was observed more frequently when vardenafil and terazosin were given simultaneously than when the<br />dosing was separated by a time interval of 6 hours.</p><p>Based on the results of interaction studies conducted with vardenafil in patients with benign prostatic<br />hyperplasia (BPH) on stable tamsulosin, terazosin or alfuzosin therapy:<br />&bull; When vardenafil (film-coated tablets) was given at doses of 5, 10 or 20 mg on a background of stable<br />therapy with tamsulosin, there was no symptomatic reduction in blood pressure, although 3/21<br />tamsulosin treated subjects exhibited transient standing systolic blood pressures of less than 85 mmHg.</p><p>&bull; When vardenafil 5 mg (film-coated tablets) was given simultaneously with terazosin 5 or 10 mg, one<br />of 21 patients experienced symptomatic postural hypotension. Hypotension was not observed when<br />vardenafil 5 mg and terazosin administration was separated by 6 hours.<br />&bull; When vardenafil (film-coated tablets) was given at doses of 5 or 10 mg on a background of stable<br />therapy with alfuzosin, compared to placebo, there was no symptomatic reduction in blood pressure.<br />Therefore, concomitant treatment should be initiated only if the patient is stable on his alpha-blocker<br />therapy. In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the<br />lowest recommended starting dose of 5mg. Penetro may be administered at any time with tamsulosin<br />or alfuzosin. With other alpha-blockers a time separation of dosing should be considered when<br />vardenafil is prescribed concomitantly (see section 4.4).<br />Penetro 10mg Orodispersible tablets should not be taken as starting dose in patients treated with alphablockers<br />(see section 4.4).<br />No significant interactions were shown when warfarin (25 mg), which is metabolised by CYP2C9, or<br />digoxin (0.375 mg) was co-administered with vardenafil (20 mg film-coated tablets). The relative<br />bioavailability of glibenclamide (3.5 mg) was not affected when co-administered with vardenafil (20<br />mg). In a specific study, where vardenafil (20 mg) was co-administered with slow release nifedipine<br />(30 mg or 60 mg) in hypertensive patients, there was an additional reduction on supine systolic blood<br />pressure of 6 mmHg and supine diastolic blood pressure of 5 mmHg accompanied with an increase in<br />heart rate of 4 bpm.<br />When vardenafil (20 mg film-coated tablets) and alcohol (mean maximum blood alcohol level of 73<br />mg/dl) were taken together, vardenafil did not potentiate the effects of alcohol on blood pressure and<br />heart rate and the pharmacokinetics of vardenafil were not altered.<br />Vardenafil (10 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid (2 x<br />81 mg).</p><p>Riociguat<br />Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors<br />were combined with riociguat. In clinical studies, riociguat has been shown to augment the<br />hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the<br />combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including<br />vardenafil, is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Penetro is not indicated for use by women. There are no studies of vardenafil in pregnant women.<br />There are no fertility data available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />As dizziness and abnormal vision have been reported in clinical trials with vardenafil, patients should be<br />aware of how they react to Penetro Orodispersible tablets, before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The adverse reactions reported with Penetro film-coated tablets or 10 mg orodispersible tablets in<br />clinical trials were generally transient and mild to moderate in nature. The most commonly reported<br />adverse drug reaction occurring in &ge; 10% of patients is headache.<br />Tabulated list of adverse reactions<br />Adverse reactions are listed according to the MedDRA frequency convention: very common (&ge;1/10),<br />common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and not<br />known (can not be estimated from available data).<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />The following adverse reactions have been reported:</p><p>System Organ<br />Class<br />Very common<br />(&ge;1/10)<br />Common<br />(&ge;1/100 to<br />&lt;1/10)<br />Uncommon<br />(&ge;1/1,000 to<br />&lt;1/100)<br />Rare<br />(&ge;1/10,000 to<br />&lt;1/1,000)<br />Not known<br />(can not be<br />estimated from<br />the available<br />data)<br />Infection and<br />infestations Conjunctivitis<br />Immune system<br />disorders<br />Allergic<br />oedema and<br />angioedema<br />Allergic<br />reaction<br />Psychiatric<br />disorders Sleep disorder Anxiety<br />Nervous system<br />disorders Headache Dizziness<br />Somnolence<br />Paraesthesia<br />and<br />dysaesthesia<br />Syncope<br />Seizure<br />Amnesia<br />Cerebral<br />haemorrhage<br />Eye disorders<br />Visual<br />disturbance<br />Ocular<br />hyperaemia<br />Visual colour<br />Increase in<br />intraocular<br />pressure<br />Lacrimation<br />increased<br />Non-arteritic<br />anterior<br />ischemic optic<br />neuropathy<br />Visual</p><p>Description of selected adverse reactions<br />Penile haemorrhage, haematospermia and haematuria have been reported in clinical trials and<br />spontaneous post-marketing data with the use of all PDE5 inhibitors, including vardenafil.<br />At a dose of 20 mg Vardenafil film-coated tablets, elderly (&ge; 65 years old) patients had higher<br />frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients<br />(&lt; 65 years old). In general, the incidence of adverse reactions (especially &ldquo;dizziness&rdquo;) has been shown<br />to be slightly higher in patients with a history of hypertension.<br />Post-marketing observations<br />Vascular disorders<br />Serious cardiovascular reactions, including cerebrovascular haemorrhage, sudden cardiac death,<br />transient ischaemic attack, unstable angina and ventricular arrhythmia have been reported postmarketing<br />in temporal association with another medicinal product in this class.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single dose volunteer studies, doses up to and including 80 mg vardenafil (film-coated tablets) per<br />day were tolerated without exhibiting serious adverse reactions.</p><p>When vardenafil was administered in higher doses and more frequently than the recommended dose<br />regimen (40 mg film-coated tablets twice daily) cases of severe back pain have been reported. This<br />was not associated with any muscle or neurological toxicity.<br />In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not<br />expected to accelerate clearance, as vardenafil is highly bound to plasma proteins and not significantly<br />eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE09.<br />Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction.<br />In the natural setting, i.e. with sexual stimulation it restores impaired erectile function by increasing<br />blood flow to the penis.<br />Penile erection is a haemodynamic process. During sexual stimulation, nitric oxide is released. It<br />activates the enzyme guanylate cyclase, resulting in an increased level of cyclic guanosine<br />monophosphate (cGMP) in the corpus cavernosum. This in turn results in smooth muscle relaxation,<br />allowing increased inflow of blood into the penis. The level of cGMP is regulated by the rate of<br />synthesis via guanylate cyclase and by the rate of degradation via cGMP hydrolysing<br />phosphodiesterases (PDEs).<br />Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5),<br />the most prominent PDE in the human corpus cavernosum. Vardenafil potently enhances the effect of<br />endogenous nitric oxide in the corpus cavernosum by inhibiting PDE5. When nitric oxide is released<br />in response to sexual stimulation, inhibition of PDE5 by vardenafil results in increased corpus<br />cavernosum levels of cGMP. Sexual stimulation is therefore required for vardenafil to produce its<br />beneficial therapeutic effects.<br />In vitro studies have shown that vardenafil is more potent on PDE5 than on other known<br />phosphodiesterases (&gt;15-fold relative to PDE6, &gt;130-fold relative to PDE1, &gt;300-fold relative to<br />PDE11, and &gt;1000-fold relative to PDE2, PDE3, PDE4, PDE7, PDE8, PDE9 and PDE10).<br />In a penile plesthysmography (RigiScan) study, vardenafil 20 mg produced erections considered<br />sufficient for penetration (60% rigidity by RigiScan) in some men as early as 15 minutes after dosing.</p><p>The overall response of these subjects to vardenafil became statistically significant, compared to<br />placebo, 25 minutes after dosing.<br />Vardenafil causes mild and transient decreases in blood pressure which, in the majority of the cases,<br />do not translate into clinical effects. The mean maximum decreases in supine systolic blood pressure<br />following 20 mg and 40 mg vardenafil were &ndash; 6.9 mmHg under 20 mg and &ndash; 4.3 mmHg under 40 mg<br />of vardenafil, when compared to placebo. These effects are consistent with the vasodilatory effects of<br />PDE5-inhibitors and are probably due to increased cGMP levels in vascular smooth muscle cells.<br />Single and multiple oral doses of vardenafil up to 40 mg produced no clinically relevant changes in the<br />ECGs of normal male volunteers.<br />A single dose, double blind, crossover, randomised trial in 59 healthy males compared the effects on<br />the QT interval of vardenafil (10 mg and 80 mg), sildenafil (50 mg and 400 mg) and placebo.<br />Moxifloxacin (400 mg) was included as an active internal control. Effects on the QT interval were<br />measured one hour post-dose (average tmax for vardenafil). The primary objective of this study was to<br />rule out a greater than 10 msec effect (i.e. to demonstrate lack of effect) of a single 80 mg oral dose of<br />vardenafil on QTc interval compared to placebo, as measured by the change in Fridericia&#39;s correction<br />formula (QTcF=QT/RR1/3) from baseline at the 1 hour post-dose time point. The vardenafil results<br />showed an increase in QTc (Fridericia) of 8 msec (90% CI: 6-9) and 10 msec (90% CI: 8-11) at 10 and<br />80 mg doses compared to placebo and an increase in QTci of 4 msec (90% CI: 3-6) and 6 msec (90%<br />CI: 4-7) at 10 and 80 mg doses compared to placebo, at one hour post-dose. At tmax, only the mean<br />change in QTcF for vardenafil 80 mg was out of the study established limit (mean 10 msec, 90% CI 8-<br />11). When using the individual correction formulae, none of the values were out of the limit.</p><p>In a separate post-marketing study of 44 healthy volunteers, single doses of 10 mg vardenafil or 50 mg<br />sildenafil were co-administered concomitantly with 400 mg gatifloxacin, a drug with comparable QT<br />effect. Both vardenafil and sildenafil showed an increase of Fridericia QTc effect of 4 msec<br />(vardenafil) and 5 msec (sildenafil) when compared to either drug alone. The actual clinical impact of<br />these QT changes is unknown.<br />Further information on clinical trials with vardenafil 10 mg orodispersible tablets<br />Efficacy and safety of vardenafil 10 mg orodispersible tablets were separately demonstrated in a broad<br />population in two studies including 701 randomized erectile dysfunction patients who were treated up<br />to 12 weeks. The distribution of patients in the predefined subgroups was covering elderly patients<br />(51%), patients with history of diabetes mellitus (29%), dyslipidemia (39%) and hypertension (40%).</p><p>In pooled data from the two vardenafil 10 mg orodispersible tablets trials, IIEF-EF domain scores<br />were significantly higher with vardenafil 10 mg orodispersible tablet versus placebo.<br />A percentage of 71% of all sexual attempts reported in the clinical trials had successful penetration<br />compared to 44% of all attempts in the placebo group. These results were also reflected in subgroups,<br />in elderly patients (65%), in patients with history of diabetes mellitus (63%), patients with history of<br />dyslipidemia (66%) and hypertension (70%) of all sexual attempts reported had successful penetration.<br />About 63% of all reported sexual attempts with vardenafil 10 mg orodispersible tablets were<br />successful in terms of erection maintenance compared to about 26% of all placebo-controlled sexual<br />attempts. In the predefined subgroups 57% (elderly patients), 56% (patients with history of diabetes<br />mellitus), 59% (patients with history of dyslipidemia) and 60% (patients with history of hypertension)<br />of all reported attempts with vardenafil 10 mg orodispersible tablets were successful in terms of<br />maintenance of erection.<br />Further information on clinical trials<br />In clinical trials vardenafil was administered to over 17,000 men with erectile dysfunction (ED) aged<br />18-89 years, many of whom had multiple co-morbid conditions. Over 2,500 patients were treated with<br />vardenafil for 6 months or longer. Of these, 900 patients have been treated for one year or longer.<br />The following patient groups were represented: elderly (22%), patients with hypertension (35%),<br />diabetes mellitus (29%), ischaemic heart disease and other cardiovascular diseases (7%), chronic<br />pulmonary disease (5%), hyperlipidaemia (22%), depression (5%), radical prostatectomy (9%). The<br />following groups were not well represented in clinical trials: elderly (&gt;75 years, 2.4%), and patients<br />with certain cardiovascular conditions (see section 4.3). No clinical trials in CNS diseases (except<br />spinal cord injury), patients with severe renal or hepatic impairment, pelvic surgery (except nervesparing<br />prostatectomy) or trauma or radiotherapy and hypoactive sexual desire or penile anatomic<br />deformities have been performed.</p><p>Across the pivotal trials, treatment with vardenafil (film-coated tablets) resulted in an improvement of<br />erectile function compared to placebo. In the small number of patients who attempted intercourse up to<br />four to five hours after dosing the success rate for penetration and maintenance of erection was<br />consistently greater than placebo.<br />In fixed dose studies (film-coated tablets) in a broad population of men with erectile dysfunction, 68%<br />(5 mg), 76% (10 mg) and 80% (20 mg) of patients experienced successful penetrations (SEP 2)<br />compared to 49% on placebo over a three month study period. The ability to maintain the erection</p><p>(SEP 3) in this broad ED population was given as 53% (5 mg), 63% (10 mg) and 65% (20 mg)<br />compared to 29% on placebo.<br />In pooled data from the major efficacy trials, the proportion of patients experiencing successful<br />penetration on vardenafil were as follows: psychogenic erectile dysfunction (77-87%), mixed erectile<br />dysfunction (69-83%), organic erectile dysfunction (64-75%), elderly (52-75%), ischaemic heart<br />disease (70-73%), hyperlipidaemia (62-73%), chronic pulmonary disease (74-78%), depression (59-<br />69%), and patients concomitantly treated with antihypertensives (62-73%).<br />In a clinical trial in patients with diabetes mellitus, vardenafil significantly improved the erectile<br />function domain score, the ability to obtain and maintain an erection long enough for successful<br />intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg and 20 mg. The<br />response rates for the ability to obtain and maintain an erection was 61% and 49% on 10 mg and 64%<br />and 54% on 20 mg vardenafil compared to 36% and 23% on placebo for patients who completed three<br />months treatment.</p><p>In a clinical trial in post-prostatectomy patients, vardenafil significantly improved the erectile function<br />domain score, the ability to obtain and maintain an erection long enough for successful intercourse and<br />penile rigidity compared to placebo at vardenafil doses of 10 mg and 20 mg. The response rates for the<br />ability to obtain and maintain an erection was 47% and 37% on 10 mg and 48% and 34% on 20 mg<br />vardenafil compared to 22% and 10% on placebo for patients who completed three months treatment.<br />In a flexible-dose clinical trial in patients with Spinal Cord Injury, vardenafil significantly improved<br />the erectile function domain score, the ability to obtain and maintain an erection long enough for<br />successful intercourse and penile rigidity compared to placebo. The number of patients who returned<br />to a normal IIEF domain score (&gt;26) were 53% on vardenafil compared to 9% on placebo. The<br />response rates for the ability to obtain and maintain an erection were 76% and 59% on vardenafil<br />compared to 41% and 22% on placebo for patients who completed three months treatment which were<br />clinically and statistically significant (p&lt;0.001).<br />The safety and efficacy of vardenafil was maintained in long-term studies.<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies in all<br />subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for<br />information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />In vardenafil film-coated tablets, vardenafil is rapidly absorbed with maximum observed plasma<br />concentrations reached in some men as early as 15 minutes after oral administration. However, 90% of<br />the time, maximum plasma concentrations are reached within 30 to 120 minutes (median 60 minutes)<br />of oral dosing in the fasted state. The mean absolute oral bioavailability is 15%. After oral dosing of<br />vardenafil AUC and Cmax increase almost dose proportionally over the recommended dose range (5-<br />20 mg).<br />When vardenafil film-coated tablets are taken with a high fat meal (containing 57% fat), the rate of<br />absorption is reduced, with an increase in the median tmax of 1 hour and a mean reduction in Cmax of<br />20%. Vardenafil AUC is not affected. After a meal containing 30% fat, the rate and extent of<br />absorption of vardenafil (tmax, Cmax and AUC) are unchanged compared to administration under<br />fasting conditions.<br />Vardenafil is rapidly absorbed after administration of Penetro 10mg Orodispersible tablets without<br />water. The median time to reach Cmax varied between 45 to 90 minutes and was similar or slightly<br />delayed (by 8 to 45 min) compared to the film-coated tablets. Mean vardenafil AUC was increased by<br />21 to 29% (middle aged and elderly ED patients) or 44% (young healthy subjects) with 10 mg<br />orodispersible tablets compared to film-coated tablets as a result of local oral absorption of a small<br />amount of drug in the oral cavity. There was no consistent difference in mean Cmax between<br />orodispersible tablets and film-coated tablets.<br />In subjects taking vardenafil 10 mg orodispersible tablets with a high fat meal no effect on vardenafil<br />AUC and tmax was observed, while vardenafil Cmax was reduced by 35% in the fed condition. Based<br />on these results vardenafil 10 mg orodispersible tablets can be taken with or without food.<br />If vardenafil 10 mg orodispersible tablets are taken with water, the AUC is reduced by 29%,<br />Cmax remains unchanged and median tmax is shortened by 60 minutes compared to intake without<br />water. Vardenafil 10 mg orodispersible tablets must be taken without liquid.<br />Distribution<br />The mean steady state volume of distribution for vardenafil is 208 l, indicating distribution into the<br />tissues.</p><p>Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins<br />(approximately 95% for vardenafil or M1). For vardenafil as well as M1, protein binding is<br />independent of total drug concentrations.<br />Based on measurements of vardenafil in semen of healthy subjects 90 minutes after dosing, not more<br />than 0.00012% of the administered dose may appear in the semen of patients.<br />Biotransformation<br />Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome<br />P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.<br />In humans the one major circulating metabolite (M1) results from desethylation of vardenafil and is<br />subject to further metabolism with a plasma elimination half-life of approximately 4 hours. Parts of<br />M1 are in the form of the glucuronide in systemic circulation. Metabolite M1 shows a<br />phosphodiesterase selectivity profile similar to vardenafil and an in vitro potency for<br />phosphodiesterase type 5 of approximately 28% compared to vardenafil, resulting in an efficacy<br />contribution of about 7%.<br />The mean terminal half-life of vardenafil in patients receiving Penetro 10 mg Orodispersible tablets<br />ranged between 4 &ndash; 6 hours. The elimination half-life of the metabolite M1 is between 3 to 5 hours,<br />similar to parent drug.<br />Elimination<br />The total body clearance of vardenafil is 56 l/h with a resultant terminal half-life of approximately 4-5<br />hours. After oral administration, vardenafil is excreted as metabolites predominantly in the faeces<br />(approximately 91-95% of the administered dose) and to a lesser extent in the urine (approximately 2-<br />6% of the administered dose).<br />Pharmacokinetics in special patient groups<br />Elderly<br />Hepatic clearance of vardenafil in healthy elderly volunteers (65 years and over) was reduced as<br />compared to healthy younger volunteers (18-45 years). On average elderly males taking vardenafil<br />film-coated tablets had a 52% higher AUC, and a 34% higher Cmax than younger males (see section<br />4.2).<br />Vardenafil AUC and Cmax in elderly patients (65 years or over) taking vardenafil orodispersible<br />tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison to patients aged 45&nbsp;years and below. Vardenafil was not found to accumulate in the plasma in patients aged 45 years and<br />below or 65 years or over following once-daily dosing of vardenafil 10 mg orodispersible tablets over<br />ten days.<br />Renal impairment<br />In volunteers with mild to moderate renal impairment (creatinine clearance 30-80 ml/min), the<br />pharmacokinetics of vardenafil were similar to that of a normal renal function control group. In<br />volunteers with severe renal impairment (creatinine clearance &lt;30 ml/min) the mean AUC was<br />increased by 21% and the mean Cmax decreased by 23%, compared to volunteers with no renal<br />impairment. No statistically significant correlation was observed between creatinine clearance and<br />vardenafil exposure (AUC and Cmax) (see section 4.2). Vardenafil pharmacokinetics has not been<br />studied in patients requiring dialysis (see section 4.3).<br />Hepatic impairment<br />In patients with mild to moderate hepatic impairment (Child-Pugh A and B), the clearance of<br />vardenafil was reduced in proportion to the degree of hepatic impairment. In patients with mild hepatic<br />impairment (Child-Pugh A), the mean AUC and Cmax increased by 17% and 22% respectively,<br />compared to healthy control subjects. In patients with moderate impairment (Child-Pugh B), the mean<br />AUC and Cmax increased by 160% and 133% respectively, compared to healthy control subjects (see<br />section 4.2). The pharmacokinetics of vardenafil in patients with severely impaired hepatic function<br />(Child-Pugh C) has not been studied (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.]</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmabust 500<br />Aspartame<br />Peppermint flavour.<br />Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C.<br />Keep out the sight and reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Penetro 10mg Orodispersible Tablets are packed as 4 tablets ( in Alu-Alu Blister).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>